Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 04-10 15:00:00

26.48

-0.08

-0.30%

High26.77	Low26.39	Vol15.36M
Open26.52	D1 Closing26.56	Amplitude1.43%
Mkt Cap70.70B	Tradable Cap56.08B	Total Shares2.67B
T/O408.00M	T/O Rate0.73%	Tradable Shares2.12B
P/B1.45	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":26.48,"timestamp":1775804401000,"preClose":26.56,"halted":0,"volume":15361341,"delay":0,"changeRate":-0.003,"floatShares":2118000000,"shares":2670000000,"eps":1.4872,"marketStatus":"Closed","change":-0.08,"latestTime":"04-10 15:00:00","open":26.52,"high":26.77,"low":26.39,"amount":408000000,"amplitude":0.0143,"askPrice":26.49,"askSize":272,"bidPrice":26.48,"bidSize":124,"shortable":0,"etf":0,"ttmEps":1.4872,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":26.56,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":29.22,"lowLimit":23.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.45,"roa":"--","peRate":17.805272,"roe":"7.03%","epsLYR":1.27,"committee":0.210358,"marketValue":70713000000,"turnoverRate":0.0073,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":19.96,"timestamp":1775808560004,"preClose":20.02,"halted":0,"volume":2198752,"delay":0,"premium":"-34.30"},"floatMarketCap":56098000000},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2626789199","title":"BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626789199","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626789199?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:34","pubTimestamp":1775817257,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPAApril 10  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT'S DRUG REGISTRATION APPLICATION FOR FLURBIPROFEN AXETIL INJECTION APPROVED BY NMPAFurther company coverage: 600196.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","600196","BK0096","BK0183","BK1593","BK1191","BK1515","BK0175","BK0196","BK0012","BK0187","BK0239","02196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173461200","title":"FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=1173461200","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173461200?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:44","pubTimestamp":1775814265,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","600196","BK0187","BK1515","BK0188","BK0060","BK1593","02196","BK0196","BK0183","BK0096","BK0175","BK1191","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626195105","title":"Shanghai Fosun Pharma - Unit's Drug Registration Application for Flurbiprofen Axetil Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2626195105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626195105?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:38","pubTimestamp":1775813895,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0188","BK0012","02196","BK0028","BK1515","BK0187","BK0239","BK1191","BK0175","BK0196","600196","BK0060","BK1593","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626951711","title":"Fosun Pharma unit Yaopharma wins China approval for flurbiprofen axetil injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2626951711","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626951711?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:37","pubTimestamp":1775813874,"startTime":"0","endTime":"0","summary":"Fosun Pharma unit Yaopharma won China marketing clearance for flurbiprofen axetil injection for post-surgical pain and cancer-related analgesia.Approval covers 5 ml:50 mg strength under chemicals Category 3.Fosun Pharma disclosed cumulative R&D spending of about RMB 34 million as of March 2026.IQVIA CHPA data cited 2025 China sales for flurbiprofen axetil injection at about RMB 1.2 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL548Bdv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LU1791710400.SGD","LU0477156953.USD","BK0196","LU0882574055.USD","LU1989764664.SGD","LU1201861249.SGD","LU1989764748.USD","BK4530","LU0130518102.USD","BK0028","BK4121","BK0187","BK0239","BK0060","LU1791710582.SGD","BK4585","BK4588","LU0198837287.USD","LU0648001328.SGD","LU1201861165.SGD","LU0648000940.SGD","LU0130103400.USD","BK0183","LU0130517989.USD","00656","IQV","LU0130102774.USD","BK1230","BK0012","BK0175","BK0188","BK0096","LU1261432733.SGD","LU0980610538.SGD","600196","LU0477156797.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626931221","title":"Fosun Pharma board to review first-quarter results, approve release","url":"https://stock-news.laohu8.com/highlight/detail?id=2626931221","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626931221?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:11","pubTimestamp":1775812288,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical board meeting scheduled for April 28, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL8FKbFx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0096","600196","BK0183","BK1230","BK0012","BK0196","BK0187","BK0060","BK0188","BK0239","00656","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625945204","title":"Fosun unit FPI to hold 71.42% voting rights in Sisram after reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2625945204","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625945204?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:48","pubTimestamp":1775648935,"startTime":"0","endTime":"0","summary":"Fosun Pharma began internal reorganization of its Sisram Medical stake on April 8, 2026, shifting holdings from Ample Up and Chindex to indirect unit Fosun Pharma Industrial.Ample Up will transfer 207,186,160 Sisram shares, equal to 44.2% of issued shares.Chindex will transfer 127,318,640 shares, equal to 27.2%.Completion would leave Fosun Pharma Industrial holding 334,504,800 shares, equal to 71.4% of voting rights.Regulator granted Fosun Pharma waiver from mandatory general offer requirement tied to voting rights increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  ,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL4bnYMr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","BK0239","BK0060","BK1585","BK1593","BK0188","BK1100","BK0187","BK0096","BK0183","01696","600196","BK0196","BK0012","BK0028","00656","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624863192","title":"Fosun Pharmaceutical Names CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2624863192","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624863192?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:38","pubTimestamp":1775183882,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) appointed Huang Zhi as chief financial officer, according to a Friday disclosure on the Shanghai bourse.Huang, who was also appointed as senior vice president, will take over from Chen Zhanyu, who resigned due to adjustments in work arrangements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0012","600196","BK0028","02196","BK0187","BK0196","BK0183","BK0175","BK1515","BK0096","BK1191","BK0188","BK1593","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624602575","title":"Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2624602575","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624602575?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:11","pubTimestamp":1775113869,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's   subsidiary, Shanghai Henlius Biotech, received approval from China's National Medical Products Administration for the phase I clinical trial of HLX319, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for early and metastatic breast cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0175","02196","BK0187","BK0183","BK0012","600196","BK1593","BK0196","BK0188","BK1515","BK0239","BK0096","BK1191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160987954","title":"FOSUN PHARMA Subsidiary Receives Clinical Trial Approval for HLX319 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1160987954","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160987954?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:00","pubTimestamp":1775034024,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities recently obtained approval from the National Medical Products Administration. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0175","02196","BK0187","BK0183","BK0012","600196","BK1593","BK0196","BK0188","BK1515","BK0239","BK0096","BK1191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624566319","title":"Fosun Pharmaceutical to Set Up Parallel Fund Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2624566319","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624566319?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:48","pubTimestamp":1775015336,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","600196","BK1515","BK0012","BK0188","BK0196","BK0060","BK0175","BK0187","BK1191","BK1593","BK0183","BK0096","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589274","title":"Fosun Pharma Unit Gets China Nod for Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589274","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589274?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:23","pubTimestamp":1774959820,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   unit Shanghai Fosun Pharmaceutical Industrial Development obtained clinical trial approval for FXB0871 from China's National Medical Products Administration.The pharmaceutical firm aims to study the drug for the treatment of locally advanced or metastatic solid tumors.The company will begin the study once conditions are met.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0028","BK1593","BK0183","BK0012","BK0096","BK1191","BK0188","BK0187","BK0175","BK1515","BK0239","02196","600196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300050","title":"BRIEF-Shanghai Fosun Pharma Announces Approval From NMPA For Clinical Trial Of FXB0871","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300050","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623300050?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:27","pubTimestamp":1774952855,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Announces Approval From NMPA For Clinical Trial Of FXB0871March 31 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:APPROVAL FROM NMPA FOR CLINICAL TRIAL OF FXB0871Further company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0239","BK0188","BK0183","BK1593","02196","BK0096","BK1191","BK0012","BK0196","BK0060","BK0187","BK0028","BK1515","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623530076","title":"Shanghai Fosun Pharma -  Approval From Nmpa for Clinical Trial of Fxb0871","url":"https://stock-news.laohu8.com/highlight/detail?id=2623530076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623530076?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:24","pubTimestamp":1774952640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0060","BK0183","600196","BK0012","BK0028","BK0188","BK0239","BK1515","BK1593","BK0187","02196","BK0096","BK0175","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150757174","title":"FOSUN PHARMA Reports 2025 Results: Revenue Hits 41.7B Yuan with 21.7% Net Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1150757174","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150757174?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:04","pubTimestamp":1774447444,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA has achieved a strategic upgrade in its internationalization process, moving from \"product globalization\" to \"system globalization.\" On March 24, FOSUN PHARMA released its 2025 annual...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","06978","BK1593","BK1191","BK0096","BK0183","BK0175","BK0012","600196","BK1161","159992","BK1574","BK0028","BK0187","BK1515","BK0196","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128354105","title":"FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1128354105","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128354105?lang=en_us&edition=fundamental","pubTime":"2026-03-25 11:00","pubTimestamp":1774407628,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million. On the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0239","BK0188","BK0183","BK1593","02196","BK0096","BK1191","BK0012","BK0196","BK0060","BK0187","BK0028","BK1515","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188078231","title":"FOSUN PHARMA Declares Final Dividend of HK$0.39 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1188078231","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188078231?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:36","pubTimestamp":1774395373,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced its plan to distribute a final dividend of HK$0.39 per share.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VIG","BK4585","BK0239","600196","BK0012","BK1515","BK0175","BK0183","BK0187","02196","BK0188","BK1593","BK1191","BK0096","BK0028","BK0196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622401954","title":"Fosun Pharma proposed a RMB 0.39 per share final dividend for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401954","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622401954?lang=en_us&edition=fundamental","pubTime":"2026-03-25 06:21","pubTimestamp":1774390911,"startTime":"0","endTime":"0","summary":"Fosun Pharma proposed a final dividend of RMB 0.39 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7vNqq9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0060","BK0183","BK1230","BK0012","BK0187","BK0028","BK0196","BK0239","BK0188","00656","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001939","title":"Shanghai Fosun Pharma - Proposed to Distribute Cash Dividend of RMB0.39 for Each Ordinary Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001939?lang=en_us&edition=fundamental","pubTime":"2026-03-25 06:18","pubTimestamp":1774390722,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXBAF9F2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02196","BK0012","600196","BK0183","BK1515","BK0060","BK0187","BK0196","BK0239","BK1191","BK1593","BK0028","BK0175","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621951910","title":"Press Release: Fosun Pharma Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621951910","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621951910?lang=en_us&edition=fundamental","pubTime":"2026-03-24 22:47","pubTimestamp":1774363620,"startTime":"0","endTime":"0","summary":"Innovation and Globalization Propel Fosun Pharma's High-Quality Growth. SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma , an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating results .Powered by the dual engines of innovation and globalization, Fosun Pharma achieved total operating revenue of RMB 41.662 billion, up 1.45% year-on-year. Of this, revenue from innovative drugs reached RMB 9.893 billion, rising 29.59% year-on-year; overseas revenue amounted to RMB 12.977 billion, growing 14.87% year-on-year. Net profit attributable to shareholders of the parent company was RMB 3.371 billion, up 21.69% year-on-year; recurring net profit attributable to shareholders of the parent company amounted to RMB 2.34 billion, increasing 1.12% year-on-year; and net cash flow generated from operating activities reached RMB 5.213 billion, up 16.45% year-on-year, further consolidating the foundation for high-quality development.Oncol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0012","R","BK1191","BK1515","BK0175","BK1593","600196","BK4232","BK0183","BK0196","BK0028","BK4022","BK0239","02196","BK0188","BK0187","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060397","title":"Fosun Pharma reports JediVision lung nodule navigation device approval in June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621060397?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:14","pubTimestamp":1774358051,"startTime":"0","endTime":"0","summary":"Fosun Pharma reported that its AI-enabled surgical navigation device, JediVision lung nodule marking and positioning equipment, was approved for market launch in June.The company said the launch aligns with its FoSTRAID strategy to embed AI and data science across R&D and commercialization, aiming to strengthen pipeline decision-making and operational execution.Fosun Pharma reported R&D spending of CNY 5.91 billion, with 72.77% allocated to innovation-drug programs, positioning the company to scale AI-supported development alongside its broader innovation portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8PKZtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK1230","BK0012","BK0028","BK0183","BK0187","600196","BK0060","BK0188","BK0096","BK0196","00656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":0.0149},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0951},{"period":"1year","weight":0.1347},{"period":"ytd","weight":0.0026}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":-0.0381},{"period":"3month","weight":-0.0374},{"period":"6month","weight":0.0177},{"period":"1year","weight":0.2446},{"period":"ytd","weight":-0.0007}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","serverTime":1775818935689,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction